SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. Fundamental Analysis
SpringWorks Therapeutics, Inc. (SWTX) shows moderate financial fundamentals with a PE ratio of -16.44, profit margin of -1.34%, and ROE of -44.86%. The company generates $0.2B in annual revenue with strong year-over-year growth of 34.17%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -97.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SWTX's fundamental strength across five key dimensions:
Efficiency Score
WeakSWTX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSWTX trades at attractive valuation levels.
Growth Score
ExcellentSWTX delivers strong and consistent growth momentum.
Financial Health Score
ExcellentSWTX maintains a strong and stable balance sheet.
Profitability Score
WeakSWTX struggles to sustain strong margins.
Key Financial Metrics
Is SWTX Expensive or Cheap?
P/E Ratio
SWTX trades at -16.44 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SWTX's PEG of -8.17 indicates potential undervaluation.
Price to Book
The market values SpringWorks Therapeutics, Inc. at 8.43 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -16.39 times EBITDA. This is generally considered low.
How Well Does SWTX Make Money?
Net Profit Margin
For every $100 in sales, SpringWorks Therapeutics, Inc. keeps $-1.34 as profit after all expenses.
Operating Margin
Core operations generate -1.37 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-44.86 in profit for every $100 of shareholder equity.
ROA
SpringWorks Therapeutics, Inc. generates $-42.35 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
SpringWorks Therapeutics, Inc. generates limited operating cash flow of $-124.40M, signaling weaker underlying cash strength.
Free Cash Flow
SpringWorks Therapeutics, Inc. generates weak or negative free cash flow of $-121.06M, restricting financial flexibility.
FCF Per Share
Each share generates $-1.61 in free cash annually.
FCF Yield
SWTX converts -3.40% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-16.44
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-8.17
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.43
vs 25 benchmark
P/S Ratio
Price to sales ratio
22.14
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.33
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.45
vs 25 benchmark
ROA
Return on assets percentage
-0.42
vs 25 benchmark
ROCE
Return on capital employed
-0.52
vs 25 benchmark
How SWTX Stacks Against Its Sector Peers
| Metric | SWTX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -16.44 | 29.43 | Better (Cheaper) |
| ROE | -44.86% | 800.00% | Weak |
| Net Margin | -133.81% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.02 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 4.33 | 4.64 | Strong Liquidity |
| ROA | -42.35% | -17936.00% (disorted) | Weak |
SWTX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews SpringWorks Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-173.47%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-114.71%
Industry Style: Defensive, Growth, Innovation
Declining